comprehensive -WSS

comprehensive

author：leisure time 2025-09-05 07:02:43 - browse：48477

novavax photo illo — JUSTIN TALLIS/AFP via Getty Images

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Hello, all. Damian here with an update on the plight of the other Covid-19 vaccine company, Wall Street’s latest GLP-1 trade, and the quest for a universal antivenom.

The need-to-know this morning

Ocular Therapeutics announced a shakeup of its senior management team and a $325 million private placement.
Amylyx Therapeutics said results from a closely followed Phase 3 study of its treatment for ALS could come before the start of the second quarter — earlier than previously expected.
Moderna earnings are here.

Novavax’s money is going in the wrong direction

The good news for Novavax is that it’s no longer facing a $700 million dispute with a global charity organization. The bad news is that settling that dispute will force the struggling company to pay out $400 million over the next five years.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： Readout Newsletter: PTC, Dyne, Rapport, Cytokinetics news

Wikipedia

focus

WSS

Acelyrin, a rare IPO success, stumbles in its first big test

White House touts steps to stem shortages of cancer treatments

AI for drug discovery: Experts on separating hype from reality

Novel spinal cord stimulator treats paralysis without surgery

Long Covid needs a new name — and a new frame

FDA approves updated Covid vaccines

focus

comprehensive

The need-to-know this morning

Novavax’s money is going in the wrong direction

entertainment

In Memoriam: Notable people who died in 2023

Most antidepressants don't work on kids, teens, study finds

Medical records are filled with copy

How medical schools plan to diversify without affirmative action

ChatGPT in medicine: STAT answers readers' burning questions

Walmart eyes Medicare Advantage provider ChenMed

Bright Health sells Medicare Advantage business to Molina

PEPFAR is under serious threat — and so is global health

DIEP, the 'gold standard' of breast reconstruction, is under threat

WATCH: Why do bright lights make us see spots?

hotspot

How medical schools plan to diversify without affirmative action

PEPFAR is under serious threat — and so is global health

How housing is health care on Long Island

Primary care doctor shortage won't be solved by free med school tuition

What to make of Biden’s latest efforts on cancer research

The effects of a landmark ruling on DNA ownership are becoming clearer

Wikipedia

focus

hotspot

hotspot